SCHEMBL20347486

SCHEMBL20347486

CC(C)C1=C(C(C)C)NCCCC1

nearest known ligand 0.36

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
FKBP5 Q13451 1/20 0.36
CRBN Q96SW2 1/20 0.36
ALDH1A1 P00352 1/20 0.30
CASP1 P29466 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13172081 0.93 OR51E2 (0.33)
SCHEMBL305774 0.71
SCHEMBL13228792 0.70 OR51E2 (0.33)
SCHEMBL13228780 0.70 OR51E2 (0.33)
SCHEMBL24016158 0.68
SCHEMBL24373238 0.68 OR51E2 (0.32)
SCHEMBL24856227 0.65 OR51E2 (0.30)
SCHEMBL25144066 0.65 OR51E2 (0.30)
SCHEMBL19059613 0.65 OR51E2 (0.30)
SCHEMBL23194555 0.65

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11713299-B2 Histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-08-01 US disclosed
US-11713299-B2 Histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-08-01 US disclosed
US-20210107876-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2021-04-15 US disclosed
US-10829452-B2 Histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2020-11-10 US disclosed
US-20180186745-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2018-07-05 US disclosed
US-20180186745-A1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS, INC. 2018-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180186745-A1 HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, EZH2 FKBP5 4839/4885CRBN 1921/4885ALDH1A1 1839/4885
US-10829452-B2 Histone methyltransferase inhibitors EHMT1, DOT1L, EHMT2 FKBP5 4855/4885CRBN 1323/4885ALDH1A1 492/4885
US-20210107876-A1 HISTONE METHYLTRANSFERASE INHIBITORS EHMT1, EHMT2, EZH2 FKBP5 4839/4885CRBN 1921/4885ALDH1A1 1839/4885
US-11713299-B2 Histone methyltransferase inhibitors EHMT1, DOT1L, EHMT2 FKBP5 4854/4885CRBN 1269/4885ALDH1A1 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.